Abbott (ABT) Expands In Europe With Instinct CGM And Emerging Market Medicines

• Abbott Laboratories (NYSE:ABT) is rolling out its Instinct continuous glucose monitoring sensor across Europe as part of MiniMed insulin pump systems.
• The integration brings Abbott's CGM technology directly into new automated insulin delivery platforms for diabetes patients.
• At the same time, Abbott is increasing its presence in emerging markets through biosimilar and branded generic medicine launches and regulatory approvals.

For investors watching Abbott Laboratories, these moves connect two core pieces of the company: diabetes technology in developed markets and medicines in faster growing emerging regions. The Instinct CGM rollout with MiniMed in Europe positions Abbott inside more insulin pump ecosystems at a time when automated insulin delivery is a key focus for diabetes care.

On the medicines side, broader biosimilar and branded generic activity in emerging markets gives Abbott more exposure to healthcare demand outside the US and Europe. Together, these developments point to a wider commercial footprint for NYSE:ABT across devices and pharmaceuticals, which many investors track closely when assessing how diversified healthcare companies are positioned.

Stay updated on the most important news stories for Abbott Laboratories by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Abbott Laboratories.

Is Abbott Laboratories's dividend sustainable? Check out what every dividend investor needs to know in our dividend analysis.

Quick Assessment

• ✅ Price vs Analyst Target: At US$93.24, Abbott Laboratories trades about 20% below the US$116.54 analyst price target.
• ✅ Simply Wall St Valuation: Shares are described as trading 33.7% below the estimated fair value, which screens as undervalued.
• ✅ Recent Momentum: The stock is up 7.6% over the last 30 days.

There's only one way to know the right time to buy, sell or hold Abbott Laboratories. Head to Simply Wall St's company report for the latest analysis of Abbott Laboratories's Fair Value.

Key Considerations

• 📊 The Instinct CGM rollout with MiniMed and expanding biosimilar and branded generic footprint in emerging markets both support Abbott Laboratories’ mix of devices and medicines.
• 📊 Investors may want to watch uptake of Instinct CGM in European pump systems, growth contributions from emerging markets, and how these tie into earnings and revenue trends.
• ⚠️ Profit margins of 13.9% are lower than last year’s 31.9%, and Abbott Laboratories is flagged as having a high level of debt, which can influence how attractive this expansion looks.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Abbott Laboratories analysis. Alternatively, you can check out the community page for Abbott Laboratories to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com